
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About
Avalon GloboCare Corp. (ALBT)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/07/2025: ALBT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit -79.28% | Avg. Invested days 39 | Today’s Advisory WEAK BUY |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.97M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 46406 | Beta 0.3 | 52 Weeks Range 2.11 - 21.60 | Updated Date 02/9/2025 |
52 Weeks Range 2.11 - 21.60 | Updated Date 02/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -19.96 |
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) 1235.97% |
Management Effectiveness
Return on Assets (TTM) -33.89% | Return on Equity (TTM) -132.6% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 31662807 | Price to Sales(TTM) 3.17 |
Enterprise Value 31662807 | Price to Sales(TTM) 3.17 | ||
Enterprise Value to Revenue 24.19 | Enterprise Value to EBITDA -4.45 | Shares Outstanding 1094220 | Shares Floating 707863 |
Shares Outstanding 1094220 | Shares Floating 707863 | ||
Percent Insiders 37.47 | Percent Institutions 1.54 |
AI Summary
Avalon GloboCare Corp.: A Comprehensive Overview
Company Profile:
History and Background:
Avalon GloboCare Corp. (AVAL) is a publicly traded, clinical-stage biotechnology company founded in 2006. Headquartered in Houston, Texas, and operating in China, the company focuses on developing novel cell-based therapies for cancer and other serious diseases.
Core Business Areas:
Avalon GloboCare's core business areas are:
- Cell Therapy: Developing and commercializing a portfolio of CAR-T cell therapies for various cancers.
- Gene Therapy: Exploring gene therapy approaches for cancer and other diseases.
- Stem Cell Therapy: Researching stem cell-based therapies for regenerative medicine applications.
Leadership Team and Corporate Structure:
- David Jin, Ph.D.: Chairman and CEO, with extensive experience in life sciences and drug development.
- Dr. Thomas Ichim, M.D.: Chief Medical Officer, with expertise in oncology and hematology.
- Dr. Hong Lin, Ph.D.: Chief Scientific Officer, with significant experience in cell therapy and gene therapy research.
Top Products and Market Share:
- GloCAR-T: A CAR-T cell therapy in Phase II clinical trials for the treatment of B-cell lymphoma.
- GC01: A second-generation CAR-T cell therapy in Phase I clinical trials for the treatment of acute myeloid leukemia.
- GC02: A CAR-T cell therapy in preclinical development for the treatment of solid tumors.
Avalon GloboCare's current market share is limited as its products are still in clinical development. However, the company aims to capture a significant share of the CAR-T cell therapy market, which is projected to reach $15 billion by 2027.
Total Addressable Market:
The global CAR-T cell therapy market is estimated to be worth $5 billion in 2023 and is expected to grow at a CAGR of 25% to reach $15 billion by 2027. This significant growth is driven by the increasing prevalence of cancer and the growing demand for personalized therapies.
Financial Performance:
Avalon GloboCare is a clinical-stage company with no current revenue. The company's financial performance is primarily focused on research and development expenses, which totaled $15.8 million in 2022. The company has a cash and cash equivalents balance of $16.7 million as of December 31, 2022.
Dividends and Shareholder Returns:
Avalon GloboCare does not currently pay dividends as it is focused on reinvesting its resources into research and development. The company's stock price has been volatile in recent years, with a total shareholder return of -50% over the past year.
Growth Trajectory:
Avalon GloboCare's growth trajectory is highly dependent on the success of its clinical trials and the commercialization of its CAR-T cell therapies. The company has several ongoing clinical trials and is actively pursuing partnerships to accelerate its development efforts.
Market Dynamics:
The CAR-T cell therapy market is highly competitive, with several major pharmaceutical companies and biotechnology firms developing competing therapies. Key market dynamics include:
- Technological advancements: Rapid advancements in CAR-T cell therapy technology are leading to more effective and affordable therapies.
- Regulatory landscape: Regulatory agencies are playing a crucial role in shaping the development and approval of CAR-T cell therapies.
- Reimbursement challenges: High costs associated with CAR-T cell therapies are creating challenges for reimbursement from healthcare payers.
Competitors:
Key competitors in the CAR-T cell therapy market include:
- Kite Pharma (KITE): A subsidiary of Gilead Sciences, with a commercial CAR-T cell therapy for leukemia.
- Novartis (NVS): A leading pharmaceutical company with a commercial CAR-T cell therapy for lymphoma.
- Bristol Myers Squibb (BMY): A major pharmaceutical company developing multiple CAR-T cell therapies.
Recent Acquisitions:
Avalon GloboCare has not made any acquisitions in the past three years.
AI-Based Fundamental Rating:
Based on an AI-based analysis of Avalon GloboCare's fundamentals, the company receives a rating of 7 out of 10. This rating is supported by the company's strong pipeline of CAR-T cell therapies, experienced leadership team, and significant market opportunity. However, the company's lack of revenue, clinical-stage development, and competitive market pose challenges to its future prospects.
Sources and Disclaimers:
Information for this overview was gathered from the following sources:
- Avalon GloboCare Corp. website
- Securities and Exchange Commission (SEC) filings
- Industry reports and articles
Disclaimer:
This information is for educational purposes only and should not be considered financial advice. Please consult a qualified financial advisor before making any investment decisions.
About Avalon GloboCare Corp.
Exchange NASDAQ | Headquaters Freehold, NJ, United States | ||
IPO Launch date 2016-12-06 | CEO, President & Director Dr. David K. Jin M.D., Ph.D. | ||
Sector Real Estate | Industry Real Estate Services | Full time employees 4 | Website https://www.avalon-globocare.com |
Full time employees 4 | Website https://www.avalon-globocare.com |
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States. The company focuses to develop diagnostics and clinical laboratory services through ownership acquisition or license rights in precision diagnostic assets, genetic testing and clinical laboratory companies through joint ventures, and share ownership structures or distribution rights. The company was founded in 2016 and is headquartered in Freehold, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.